News
Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback